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Abstract
Genome-wide association studies have revealed several common genetic risk variants for
ulcerative colitis (UC). However, little is known about the contribution of rare, large effect
genetic variants to UC susceptibility. In this study, we performed a deep targeted re-
sequencing of 122 genes in Dutch UC patients in order to investigate the contribution of
rare variants to the genetic susceptibility to UC. The selection of genes consists of 111
established human UC susceptibility genes and 11 genes that lead to spontaneous colitis
when knocked-out in mice. In addition, we sequenced the promoter regions of 45 genes
where known variants exert cis-eQTL-effects. Targeted pooled re-sequencing was per-
formed on DNA of 790 Dutch UC cases. The Genome of the Netherlands project provided
sequence data of 500 healthy controls. After quality control and prioritization based on allele
frequency and pathogenicity probability, follow-up genotyping of 171 rare variants was per-
formed on 1021 Dutch UC cases and 1166 Dutch controls. Single-variant association and
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gene-based analyses identified an association of rare variants in theMUC2 gene with UC.
The associated variants in the Dutch population could not be replicated in a German replica-
tion cohort (1026 UC cases, 3532 controls). In conclusion, this study has identified a puta-
tive role forMUC2 on UC susceptibility in the Dutch population and suggests a population-
specific contribution of rare variants to UC.
Introduction
Inflammatory bowel diseases (IBD) are common chronic gastrointestinal inflammatory disor-
ders. The two major forms of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). CD
can affect any part of the gastrointestinal tract, while UC is restricted to the colon and the rec-
tum. UC is probably caused by an aberrant immune response against the commensal intestinal
flora, influenced by a combination of genetic, microbial and environmental factors, resulting in
chronic inflammation of the colonic epithelium. Defects in both innate and adaptive immunity
and epithelial barrier function are associated with UC[1].
The genetics of complex diseases has been thoroughly investigated in genome wide associa-
tion studies (GWAS). These identified thousands of common genetic variants associated with
disease susceptibility[2]. GWAS and meta-analyses have identified 200 risk loci in IBD, includ-
ing 29 risk loci specifically associated with UC. While relevant disease pathways have been
identified by GWAS, UC-associated common variants only explain 8.2% of variance in disease
onset[3]. Therefore, research looking into the missing heritability in UC is now focused on the
contribution of low frequency and rare variants[4,5].
Sequencing studies have revealed that low frequency (minor allele frequency (MAF)
between 1% and 5%) and rare (MAF< 1%) genetic variants are more likely to have a deleteri-
ous effect on health compared to common variants (MAF> 5%)[6]. Also, population-based
studies characterizing detailed genetic variation within a population, like the Genome of The
Netherlands (GoNL), have shown that rare genetic variants can be very population-specific[7].
So far, four re-sequencing studies investigating IBD in European populations have been per-
formed[8–11]. Only one of these studies focused on UC[10]. These four studies showed that
low frequency and rare protein coding variants in four genes (NOD2, IL23R, CARD9 and
BTNL2) are associated with IBD (p< 1 x 10−6). Six additional genes (IL18RAP, CUL2,
C1orf106, PTPN22,MUC19 and RNF186) are suggestively associated with IBD (p< 0.0001)
[8,10,11,9].
Since rare variants are population-specific and only one previous study investigated UC, we
aimed to further investigate the contribution of rare, large effect genetic variants to UC suscep-
tibility. We identified a putative role of variants in theMUC2 gene on UC susceptibility in
the Dutch population and suggest a population-specific contribution of rare variants to UC
liability.
Materials and Methods
We performed a targeted resequencing study in 790 UC patients (Phase I) followed by replica-
tion of identified variants in an independent Dutch cohort of 1021 UC cases and 1161 Healthy
controls (Phase II) and a German cohort consisting of 1026 UC cases and 3532 healthy con-
trols (Phase III).
Pooled targeted deep high-throughput sequencing has been performed of 122 genes: We
have selected two groups of target genes for re-sequencing.
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The first group of genes (n = 111) originates from genomic loci identified through previous
GWAS and Immunochip studies conducted by the International IBD Genetics Consortium
[12], The second group consisted of genes selected based on the fact that they lead to the devel-
opment of a spontaneous colitis in knock-out mice (n = 11) [13] (Phase I). (S1 File) In addition
to the coding sequence, for 45 of these genes with a known cis-eQTL effect (expression Quanti-
tative Trait Locus) we also sequenced the promoter region[14]. We used whole genome
sequence data of 500 healthy unrelated Dutch individuals from the Genome of the Netherlands
(GoNL) as a control cohort[7]. Follow-up genotyping of identified variants was performed in
1021 Dutch cases and 1166 healthy controls (Phase II) and in independent German cohorts of
1026 UC cases and 3532 healthy controls (Phase III). Fig 1 shows an overview of our analysis
strategy (Phases I, II and III).
Phase I: Discovery
Target selection, design and enrichment. In total, for 122 genes, we sequenced all exons
including 20 flanking intronic base pairs. In addition, for the genes with a known cis-eQTL
effect[15], we included 1000 base pairs upstream of the transcription start site in the sequenc-
ing design to enable us to identify regulatory variants in the promoter sequence of those genes.
Pooled targeted enrichment of DNA from 790 Dutch UC patients (12 individuals per pool)
was performed using a custom-made kit (Agilent HaloPlex). The HaloPlex kit was designed
with Agilent’s Sure Design, resulting in coverage of 99.9% of the target sequence (S1 File).
Sequencing, read alignment and annotation. Next, after the enrichment, the resulting
libraries were sequenced using 100 bp paired-end sequencing on an Illumina HiSeq 2500
machine with 8 barcoded pools per sequence lane. Sequences were aligned using an in house-
developed pipeline adapted for pooled sequencing (Genome Build 37, Genome Analysis
Toolkit [GATK]). To reduce false-positive SNVs, we performed a second alignment and vari-
ant calling with NextGENE software (http://www.softgenetics.com/NextGENe.html). Only
variants called by both algorithms were included for further analysis.
Chi-squared and the Fisher-exact tests with R statistical software[7] were used for associa-
tion analyses. The allele frequency was based on allele counts per Single Nucleotide Variant
(SNV). Variants were annotated using SNPeff and SeattleSeq [16,17]. To check for regulatory
functions of the variants, the Encyclopedia of DNA Elements (ENCODE)[18] was searched
using the UCSC Genome Browser[19].
Quality control and variant selection: prioritization of relevant variants. As part of our
quality control procedure several identified variants were validated by Sanger sequencing (S1
File). An overview of the quality control steps is shown in Fig 2 and described in detail in S1
File.
After quality control, a total of 2562 confidential SNVs remained (S1 Table). To prioritize
relevant variants for follow up genotyping, we removed SNVs that had been tested previously
in other studies that used the Immunochip genotyping array (n = 527)[12]. Synonymous muta-
tions (n = 335) were removed since they lack functional consequence. Next, we used the follow-
ing strategies to select non-synonymous SNVs (coding), including splice-sites, (n = 418) as
well as non-coding SNVs (n = 1282).
In the coding variant group, we used an allele frequency (AF) threshold of<0.05 for inclu-
sion of variants for follow-up genotyping since common variant (AF> 0.05) analyses within
these regions have extensively been performed within the original GWAS and Immunochip
based studies[12]. A slightly different strategy was obtained for genes that are known to lead to
spontaneous colitis when knocked-out in mice. Here the aim was to study whether genomic
variants in these genes exist in humans and whether they are associated with UC susceptibility.
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Fig 1. Overview of the screening and replication strategy for rare variants. Phase I: a) targeted re-
sequencing of 122 genes was performed in a pooled design of 790 Dutch UC cases. Five hundred healthy
individuals sequenced by the Genome of the Netherlands Project were used as a control cohort. After quality
control, 2562 high-confidence variants were further prioritized based on allele frequency and likely
pathogenicity. In total 188 SNVs were selected for replication phase 1 (Phase II), of which 171 passed the
design of five Agena Biosience iPlexes. (http://agenabio.com) b) Phase II: genotyping of 171 variants was
performed in 1021 Dutch UC cases and 1166 controls. c) Phase III: after association and gene-based
analyses, genotyping of 19 variants was performed in 1026 German UC cases and 3532 healthy German
controls.
doi:10.1371/journal.pone.0159609.g001
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In this group of genes we took a more liberal approach in selecting variants for further follow-
up and included common variants with predicted functional consequences for follow-up geno-
typing (Fig 2). After this step, 377 SNVs remained. Further prioritization was based on damag-
ing effect predicted by Polyphen (damaging effects between 0.8 and 1.0) and/or damaging
effect predicted by Sift (n = 112). We included all nonsense variants (n = 6), the variants in
splice sites (n = 4) and variants that were significantly different in AF compared to the AF in
GoNL (n = 5). We also included newly identified variants that were present in multiple pools
(n = 13). In total, 140 coding variants remained after this filtering step.
Fig 2. Overview of quality control and prioritization in Phase I. a) After pooled sequencing, a total of 7969 SNVs were
detected with a coverage of >360x (12 individuals* 30x coverage). b) All variants called by two alignment strategies were
included and filtered using a Forward/Reverse balance between 20–80%. c) Variants previously tested in a large IBD cohort with
the Immunochip (n = 527) and silent mutations (n = 335) were excluded. d) We used different strategies to select non-
synonymous SNVs (coding), including splice-sites, (n = 418) (d1) and non-coding SNVs (n = 1282) (d2). d1) The coding variants
were selected on the basis of allele frequency (AF): known SNVs with an AF > 0.05 were excluded. A different strategy was
obtained for genes that are known to lead to spontaneous colitis when in knocked-out mice. In this group of genes we took a
more liberal approach in selecting variants for further follow-up and included common variants with predicted functional
consequences for follow-up genotyping. Three hundred seventy-seven SNVs remained after this step. d2) To prioritize the non-
coding SNVs in regulatory regions, we selected 48 SNVs in a transcription factor binding site (TFBS), based on ENCODE data in
the UCSC browser e) Further prioritization was based on damaging effect prediction by Polyphen (damaging effects between
0.8 and 1.0) and/or damaging effect predicted by Sift (n = 112). We included all nonsense variants (n = 6), the variants in splice-
sites (n = 4) and variants that were significantly different in AF compared to the AF in GoNL (n = 5). We also included unknown
SNVs present in more than one pool (n = 13). f) In total, 140 coding and 48 non-coding rare variants remained after filtering.
doi:10.1371/journal.pone.0159609.g002
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To prioritize the non-coding SNVs in regulatory regions, we selected 48 SNVs in a tran-
scription factor binding site (TFBS), based on ENCODE data in the UCSC browser[19].
In total 188 SNVs were selected for replication phase 1 (Phase II), of which 171 passed the
design of five Agena Biosience iPlexes (http://agenabio.com) (S1 Table).
Phase II: Replication phase 1
Genotyping of 171 SNVs was performed in 1053 independent Dutch UC cases collected as
part of the Parelsnoer Institute cohort, and 1170 geographically matched general-population-
based Dutch controls with Agena Bioscience iPlex (http://agenabio.com). After quality control
(S1 File), the dataset consisted of 1021 UC cases, 1166 healthy controls and 111 SNVs, with a
genotype call rate of 98% (S2 Table). Allelic association analysis (χ2 test, PLINK v1.07[20])
and permutation (10,000 x) association analysis was done with the Mega-analysis of Rare Var-
iants (MARV) software with a significance cut-off p-value of p<0.05 [9]. EPACTS software
was used to perform the gene-based test SKAT-O on 45 genes (all variants with AF<0.05).
SKAT-O properly corrects for population substructure. (http://genome.sph.umich.edu/wiki/
EPACTS)[9].
In total, 19 variants were selected for replication in an independent cohort (Phase III),
including variants with a significant p-value (p< 0.05), singletons replicated in cases in Phase
II and SNVs based on the gene-based analysis. SNVs were excluded if the association was in
the opposite direction between discovery (Phase I) and replication phase 1 (Phase II).
Phase III: Replication phase 2
Next, nineteen SNVs were genotyped in 1064 German UC cases and 3576 general-population-
based German controls with the iPlex Agena Bioscience system (http://agenabio.com). After
quality control (S1 File), the dataset consisted of 1027 UC cases, 3532 healthy controls and 17
SNVs, with a genotype call rate of>99%. Permutation (10,000X) allelic association analysis
was performed with the MARV software with a cut-off p-value of p<0.05 [9].
Institutional review board approval. Written informed consent was obtained from all
participants and the study was approved by the Institutional Review Boards of all individual
participating centers:
University Medical Centre Groningen, Groningen, The Netherlands;
Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands;
Maastricht University Medical Centre, Maastricht, the Netherlands;
Leiden University Medical Centre, Leiden, the Netherlands;
Erasmus University Medical Centre, Rotterdam, the Netherlands;
VU University Medical Centre, Amsterdam, the Netherlands;
University Medical Centre Utrecht, Utrecht, the Netherlands;
Academic Medical Centre, Amsterdam, The Netherlands;
University Medical Centre Schleswig-Holstein, Kiel, Germany.
Results
Pooled targeted enrichment with Haloplex capturing resulted in coverage of 98%. The mean
total number of reads per pool was 36 million, resulting in a mean coverage per pool of 2853x,
corresponding with a mean of 238x per individual sample (range 59-450x).
In total, 7969 SNVs were detected with a coverage of>30x per individual. Fifty-two percent
of SNVs were known in dbSNP version 137. This fraction is similar to that seen in previous
studies [10]. After quality control, a total of 2562 high confidence SNVs remained, resulting
in a transition/transversion ratio ti/tv = 2.52 (S1 Table). We confirmed several previously
Population-Specific Associations of Rare Variants inMUC2 with Ulcerative Colitis
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reported rare variants in IL23R (rs41313262, rs76418789, rs11209026), CARD9 (rs141992399,
rs200735402) and JAK2 (rs41316003) (Table 1) [8–11,21]. We excluded these variants from
our follow-up because they had already been extensively tested in large cohorts. In all, 877 of
the 2562 variants (~35%) were coding variants, and the remainder were located in untranslated
regions (n = 110), putative splice sites (n = 8) and intergenic regions (n = 1567) (S1 Table). Ten
predicted “loss of function” variants were detected that had not been previously tested in UC
GWAS or Immunochip experiments, and these were prioritized for follow-up (Table 2).
In total, 188 SNVs were selected for follow-up genotyping, of which 171 passed the design
of the Agena Bioscience iPlex (Phase II). After quality control 111 SNVs remained. The rela-
tively low number of replicated SNVs results from the stringent cut-off threshold to exclude
false positives. For 30 of the 111 rare SNVs, we could not identify additional carriers in either
cases or controls. For half of the variants, we detected a discrepancy in the direction of the AF
between cases and controls in the discovery (Phase I) and replication phase 1 (Phase II). For
one singleton variant, we detected one additional carrier in the cases. For the SNVs located in a
TFBS, we detected nine additional carriers, but no significant differences in AF between the
cases and controls in the replication phase 1 (Phase II, (S2 Table).
Single marker permutation (10,000x) allelic association analysis, performed with the Mega-
analysis of Rare Variants (MARV) software, detected eight SNVs (P< 0.05) with a significant
difference in AF between cases and controls[9]. Four of these SNVs were located in the coding
region ofMUC2. The other four SNVs consisted of one stop-gain variant located in CCDC88B,
two damaging coding variants in RFTN2 andMMEL1 and one variant in a TFBS in the pro-
moter region of the PMCA gene (Table 3). Gene-based analysis with SKAT-O resulted in nine
variants in theMUC2 gene with a significant p-value of 9.2 x 10−5 (threshold p = 0.0011 after
Bonferroni correction).
In total, 19 variants were selected for replication phase 2 (Phase III). After quality control,
17 variants remained, and none of the variants were associated with UC in the German cohort
(Phase III).
Discussion
In this large Dutch sequencing study, we investigated the contribution of rare variants to the
genetic susceptibility of UC. We identified a supposed role for theMUC2 gene on UC suscepti-
bility in the Dutch population, suggesting a population-specific contribution of rare variants to
UC susceptibility. What distinguishes our study from previous re-sequencing studies is that we
include 11 genes that are known to lead to spontaneous colitis when knocked-out in mice[13].
Moreover, we include the promoter regions of genes with a known cis-eQTL effect. We have
sequenced 122 genes in 790 Dutch UC patients, using a targeted pooled sequencing approach.
After prioritization of variants with a pathogenic probability, extensive follow-up genotyping
in ~1000 additional Dutch UC cases and ~1200 healthy Dutch controls revealed an association
of variants in theMUC2 gene with UC in the Dutch population. This association was not
replicated in an independent German cohort. We also confirmed known rare variants in the
IL23R (rs41313262, rs76418789, rs11209026), CARD9 (rs141992399, rs200735402) and JAK2
(rs41316003) genes, most with similar AFs to those reported in other studies (Table 1).
Pooled sequencing has proven to be a highly cost-effective method for screening large popu-
lations. Therefore, it has been used in several re-sequencing studies in IBD [9–11,21]. A major
problem of sequencing studies is the relative high rate of false-positive SNVs. The recom-
mended approach to minimize the high false-positive rate is very deep sequencing (100x per
individual) of a large population with geographically matched individuals [22]. In this study,
we used the largest Dutch UC cohort available for discovery (Phase I) and replication phase 1
Population-Specific Associations of Rare Variants inMUC2 with Ulcerative Colitis
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(Phase II). Target enrichment was performed with HaloPlex capturing, in which genomic
DNA is fragmented by restriction enzyme digestion and circularized by hybridization to
probes. Compared to hybrid capture methods, HaloPlex is relatively quick and inexpensive. It
also requires a smaller amount of DNA and has a higher fraction of sequence reads in our
region of interest [23]. However, because of the fragmentation with restriction enzymes instead
of random fragmentation, it is impossible to exclude duplicate reads in the alignment in order
to reduce sequencing artefacts. Therefore, we used the presence of the SNVs in both forward
and reverse sequencing reads as a quality control filter, which substantially reduced the number
of false positives. Since this output cannot be deduced from our standard bioinformatics
GATK-pipeline, we did additional alignment and variant calling using the NextGene Software.
After an extensive, stringent quality control with the additional alignment, ~2500 highly confi-
dent variants remained with a minimal coverage of>59x and with a transition/transversion
ratio ti/tv = 2.52, indicative of a relatively high true-positive rate for our dataset[10,9].
Single marker association and gene-based analyses (p-value = 9.2 x 10−5) showed an associa-
tion of theMUC2 gene with UC in the Dutch population (Table 3).MUC2 was selected because
it induces spontaneous colitis when knocked out in mice[1,13,24]. TheMUC2 gene encodes a
member of the mucin protein family and is the major mucin secreted in the large intestine. The
colonic mucus layer plays a critical role in intestinal homeostasis by limiting contact between
luminal bacteria and the mucosal immune system. A defective mucosal barrier is a key feature
of active UC[25,26]; patients with UC present with a reduction of goblet cells, decreased glyco-
sylation of mucins, and absence ofMUC2 expression in goblet cells in the affected colon
mucosa. Altogether, this functional evidence supportsMUC2 as a candidate gene for UC
pathogenesis.
MUC2 has not been previously identified as an UC-associated gene. A previous small candi-
date-approach genetic association study did not show an association ofMUC2 with UC[3].
Furthermore,MUC2 has never been associated with UC in GWAS studies or meta-analyses;
the Immunochip contains just twoMUC2 SNPs and only a few were present on previous
GWAS platforms (Illumina HumanHap550). The reason for this could be the difficulty of
designing specific probes because of the homology of theMUC2 gene with other members of
the mucin protein family (MUC5AC,MUC5B,MUC6 andMUC19). This strong homology
could be a source of problems in the alignment of sequencing reads, thereby introducing false
positive SNVs. However, we were able to validate our variants using Agena Bioscience assays,
which were highly specific forMUC2 as demonstrated by blasting of our sequences in the
UCSC genome browser (http://genome.ucsc.edu). Blast output and a clusterplot ofMUC2 is
shown in the S1 file.MUC2 is a very large gene. The exonic sequence contains 49 exons and the
entireMUC2 gene product has more than 5100 amino acids in its commonest allelic form. The
size of the gene makes it more likely to detect mutations.
While our association ofMUC2 in the Dutch UC population could not be replicated in a
German cohort, this might be because our associated SNVs are population specific or because
of a lack of power. Recently, the first trans-ancestry association study in IBD was performed in
a cohort of 86,640 European individuals and 9,846 individuals of East Asian, Indian or Iranian
descent [3]. The majority of the loci found, based on common SNPs with a MAF>5%, were
shared between different ancestry groups. However, this study also found genetic heterogeneity
between divergent populations at several established risk loci driven by difference in allele fre-
quency (NOD2) or effect size (TNFSF15 and ATG16L1), or a combination of these factors
(IL23R and IRGM). Rare variants are even more likely to be specific to a particular population,
as was demonstrated by a recent sequencing study in a Korean IBD population [21]. Table 1
shows that allele frequencies for a rare variant in IL23R (rs76418789) differ strongly among
populations, even between closely related UK populations [11] in Prescott’s study and the large
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population used in the Rivas and Beaudoin studies (NIDDK consortium (North America),
Australia, Italian, Dutch, Swedish, German, UK population) [10,9]. The Korean study shows a
10x higher allele frequency compared to European populations [21]. These differences in MAF
between populations, even in ancestrally close populations, could explain the lack of replication
between our Dutch and German cohorts. There could also simply be a lack of power to detect
association in our replication phase 2 (Phase III, Table 3). For example, the CARD9 splice-site
(rs141992399) has the same allele frequency in the large population of the Rivas paper (28,000
patients and 17,570 healthy controls) as in our study, but our p-value is much higher (Table 1),
which underlines the importance of well-powered studies to detect significant rare variants.
Large whole genome sequencing (WGS) and whole exome sequencing (WES) studies in
IBD are in progress. Although we identified potential variants in TFBS, none of them were sta-
tistically significant in replication phase 1 (Phase II). Thus the WGS and WES studies will
increase the power to explore the non-coding part of the genome and the association of the
MUC2 region to UC in different populations.
Conclusions
Identifying associations of rare variants in complex diseases remains challenging, and the
approach of re-sequencing known genes might not be the key to resolving the missing herita-
bility in complex diseases like UC. The power of rare variants could be better captured in the
regulatory, non-coding part of the genome by sequencing the whole genome or, specifically,
the enhancer regions. Another option is to select genes based on pathway analyses or candidate
genes, or to use specific phenotypic populations (like early onset IBD or family based studies).
If the eventual goal is individual risk-scores for disease development, genomic interpretation of
the non-coding part of the genome is crucial. For this, large well powered WGS and WES stud-
ies are necessary to give a realistic view of the role of rare variants in complex disease.
Supporting Information
S1 File. includes supplementary list of 122 selected genes, Supplementary Methods and
Supplementary Blasting and Cluster plot example.
(DOCX)
S1 Table. Discovery phase (Phase I): complete list of 2562 SNVs after quality control.
Pooled re-sequencing of 122 UC genes in 790 Dutch UC patients resulted in 7969 SNVs. After
quality control (see material and methods, Fig 2) 2562 SNVs remained. This list provides an
overview of all 2562 SNVs including association analysis with the control cohort, annotation
and selection of variants for follow-up. Association analysis was done with the Chi-squared
and the Fisher-exact tests with R statistical software. The allele frequency was based on allele
counts per SNV. Variants were annotated using SNPeff and SeattleSeq. To check for regula-
tory functions of the variants, the Encyclopedia of DNA Elements (ENCODE) was searched
using the UCSC Genome Browser. Chromosome = chromosome number (Hg 19), Position =
base pair position (Hg 19), Chr:position = combined chromosome and position (Hg 19),
Nr_pools = number of pools (of 12 patients) in which variant is detected, SNV = rs-id if avail-
able from dbSNP137, refAllele = reference allele, altAllele = alternative allele, UC_freq =
allele frequency detected in 790 UC patients, Controls_GoNL_Freq = allele frequency
detected in 500 healthy controls of the Genome of the Netherlands cohort(GoNL), CHISQ =
p-value after Chi-squared test, FISHER = p-value after Fisher-exact test,Wash_EA_AF =
allele frequency based on European population in Exome Variant Server (http://evs.gs.
washington.edu/EVS/), 1000G_EUR_AF = allele frequency based on European population in
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1000 genomes (http://www.1000genomes.org), ExAC = allele frequency based on Exome
Aggregation Consortium (http://exac.broadinstitute.org),HGVS.c = Variant using Human
Genome Variation Society notation (DNA level),HGVS.p = If variant is coding, this field
describes the variant using Human Genome Variation Society notation(Protein level), SnpEf-
f_effect = Effect of this variant based on SnpEff, SnpEff_gene_biotype = This field is 'COD-
ING' if any transcript of the gene is marked as protein coding, SnpEff_gene_name = name of
the Gene, Selection group = genes selected in UC genes or genest hat lead to spontaneous
colitis when knocked-out in mice.DNASE1 = DNase I hypersensitive sites from ENCODE,
HISTONE = histone modification from ENCODE, POLYMERASE = polymerase subunits
from ENCODE, TFBS = Transcription Factor Binding Sites from ENCODE, DNASE1_
CELLTYPES = DNase I hypersensitive sites specific cell types from ENCODE,HISTONE_
CELLTYPES = histone modification specific cell types from ENCODE, POLYMERASE_
CELLTYPES = polymerase specific cell types from ENCODE, TFBS_CELLTYPES = Tran-
scription Factor Binding Sites specific cell types from ENCODE, PolyPhen = polymorphism
phenotyping, used to predict functional effect of human missense variant, in this study the
damaging effect cut-off is between 0.8–1.0. ClinicalAssociation = link with known clinical
association, SIFT = predicts whether an amino acid substitution affects protein function,
SNP_on_ICHIP = SNP already tested on Immunochip, Refseq = annotation based on Refer-
ence sequence database (http://www.ncbi.nlm.nih.gov/refseq/), Imputed_SNV_ICHIP = var-
iant is imputed in Immunochip dataset, using GoNL data Selected_follow-up = variants
selected for follow-up (Phase II), 140 coding variants, 48 variants based on location in Tran-
scription Factor Binding Sites.
(XLSX)
S2 Table. Replication phase 1 (Phase II): complete list of 111 SNVs after quality control.
Follow-up genotyping of 171 SNVs (after quality control) in an additional Dutch cohort
(funded by the Parelsnoer Institute) consisted of 1021 UC cases, 1166 healthy controls and 111
SNVs, with a genotype call rate of 98%. Allelic association analysis (χ2 test, PLINK v1.07) and
permutation (10,000X) association analysis was performed with the Mega-analysis of Rare
Variants (MARV) software, significance cut-off p-value of<0.05. A Gene-Based analysis was
performed with EPACTS-software, 45 genes (all variants with AF< 0.05) were tested with the
SKAT-O test. (http://genome.sph.umich.edu/wiki/EPACTS).OR = Odds Ratio, Zstat_10,000-
perm = Z-statistic (which is compared to a reference standard normal distribution) after
10,000 permutations, P_10,000perm = p-value after 10,000 permutations (MARV software).
(XLSX)
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